Andrea da Silva Santos1, Roberto Dias de Oliveira2, Everton Ferreira Lemos2, Fabiano Lima2, Ted Cohen3, Olivia Cords4, Leonardo Martinez4, Crhistinne Gonçalves2, Albert Ko3, Jason R Andrews4, Julio Croda2,3,5. 1. Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Brazil. 2. School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Brazil. 3. Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, Connecticut, USA. 4. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA. 5. Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Brazil.
Abstract
BACKGROUND: Tuberculosis (TB) is a major cause of morbidity and mortality among incarcerated populations globally. We performed mass TB screening in 3 prisons and assessed yield, efficiency, and costs associated with various screening algorithms. METHODS: Between 2017 and 2018, inmates from 3 prisons in Brazil were screened for TB by symptom assessment, chest radiography, sputum testing by Xpert MTB/RIF fourth-generation assay, and culture. Chest radiographs were scored by an automated interpretation algorithm (Computer-Aided Detection for Tuberculosis [CAD4TB]) that was locally calibrated to establish a positivity threshold. Four diagnostic algorithms were evaluated. We assessed the yield (percentage of total cases found) and efficiency (prevalence among those screened) for each algorithm. We performed unit costing to estimate the costs of each screening or diagnostic test and calculated the cost per case detected for each algorithm. RESULTS: We screened 5387 prisoners, of whom 214 (3.9%) were diagnosed with TB. Compared to other screening strategies initiated with chest radiography or symptoms, the trial of all participants with a single Xpert MTB/RIF sputum test detected 74% of all TB cases at a cost of US$249 per case diagnosed. Performing Xpert MTB/RIF screening tests only on those with symptoms had a similar cost per case diagnosed (US$255) but missed 35% more cases (73 vs 54) as screening all inmates. CONCLUSIONS: In this prospective study in 3 prisons in a high TB burden country, we found that testing all inmates with sputum Xpert MTB/RIF was a sensitive approach, while remaining cost-efficient. These results support use of Xpert MTB/RIF for mass screening in TB-endemic prisons.
BACKGROUND:Tuberculosis (TB) is a major cause of morbidity and mortality among incarcerated populations globally. We performed mass TB screening in 3 prisons and assessed yield, efficiency, and costs associated with various screening algorithms. METHODS: Between 2017 and 2018, inmates from 3 prisons in Brazil were screened for TB by symptom assessment, chest radiography, sputum testing by Xpert MTB/RIF fourth-generation assay, and culture. Chest radiographs were scored by an automated interpretation algorithm (Computer-Aided Detection for Tuberculosis [CAD4TB]) that was locally calibrated to establish a positivity threshold. Four diagnostic algorithms were evaluated. We assessed the yield (percentage of total cases found) and efficiency (prevalence among those screened) for each algorithm. We performed unit costing to estimate the costs of each screening or diagnostic test and calculated the cost per case detected for each algorithm. RESULTS: We screened 5387 prisoners, of whom 214 (3.9%) were diagnosed with TB. Compared to other screening strategies initiated with chest radiography or symptoms, the trial of all participants with a single Xpert MTB/RIF sputum test detected 74% of all TB cases at a cost of US$249 per case diagnosed. Performing Xpert MTB/RIF screening tests only on those with symptoms had a similar cost per case diagnosed (US$255) but missed 35% more cases (73 vs 54) as screening all inmates. CONCLUSIONS: In this prospective study in 3 prisons in a high TB burden country, we found that testing all inmates with sputum Xpert MTB/RIF was a sensitive approach, while remaining cost-efficient. These results support use of Xpert MTB/RIF for mass screening in TB-endemic prisons.
Authors: Alimuddin Zumla; Andrew George; Virendra Sharma; Rt Hon Nick Herbert; Aaron Oxley; Matt Oliver Journal: Lancet Glob Health Date: 2015-01 Impact factor: 26.763
Authors: D M Pelissari; D C Kuhleis; P Bartholomay; D Barreira; C L P Oliveira; R S de Jesus; L A Possa; C A Jarczewski; L T Nemeth; N D de Araujo; P B L Alves; R de Souza; D Arakaki; D B Dal Molin; P Werlang; M Brouwer Journal: Int J Tuberc Lung Dis Date: 2018-10-01 Impact factor: 2.373
Authors: Nguyen Binh Hoa; Dinh Ngoc Sy; Nguyen Viet Nhung; Edine W Tiemersma; Martien W Borgdorff; Frank G J Cobelens Journal: Bull World Health Organ Date: 2010-02-22 Impact factor: 9.408
Authors: S Soemantri; F P Senewe; D H Tjandrarini; R Day; C Basri; D Manissero; F Mehta; C Dye Journal: Int J Tuberc Lung Dis Date: 2007-04 Impact factor: 2.373
Authors: Claudia M Denkinger; Sandra V Kik; Daniela Maria Cirillo; Martina Casenghi; Thomas Shinnick; Karin Weyer; Chris Gilpin; Catharina C Boehme; Marco Schito; Michael Kimerling; Madhukar Pai Journal: J Infect Dis Date: 2015-04-01 Impact factor: 5.226
Authors: Paul M Bourdillon; Crhistinne C M Gonçalves; Daniele Maria Pelissari; Denise Arakaki-Sanchez; Albert I Ko; Julio Croda; Jason R Andrews Journal: Emerg Infect Dis Date: 2017-03 Impact factor: 6.883
Authors: Tarub S Mabud; Maria de Lourdes Delgado Alves; Albert I Ko; Sanjay Basu; Katharine S Walter; Ted Cohen; Barun Mathema; Caroline Colijn; Everton Lemos; Julio Croda; Jason R Andrews Journal: PLoS Med Date: 2019-01-24 Impact factor: 11.069
Authors: F Naufal; L H Chaisson; K O Robsky; P Delgado-Barroso; H S Alvarez-Manzo; C R Miller; A E Shapiro; J E Golub Journal: Int J Tuberc Lung Dis Date: 2022-06-01 Impact factor: 3.427
Authors: Paulo César Pereira Dos Santos; Andrea da Silva Santos; Roberto Dias de Oliveira; Bruna Oliveira da Silva; Thiego Ramon Soares; Leonardo Martinez; Renu Verma; Jason R Andrews; Julio Croda Journal: Clin Infect Dis Date: 2022-07-06 Impact factor: 20.999
Authors: Katharine S Walter; Paulo César Pereira Dos Santos; Thais Oliveira Gonçalves; Bruna Oliveira da Silva; Andrea da Silva Santos; Alessandra de Cássia Leite; Alessandra Moura da Silva; Flora Martinez Figueira Moreira; Roberto Dias de Oliveira; Everton Ferreira Lemos; Eunice Cunha; Yiran E Liu; Albert I Ko; Caroline Colijn; Ted Cohen; Barun Mathema; Julio Croda; Jason R Andrews Journal: Lancet Reg Health Am Date: 2022-02-01
Authors: Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne Journal: Cochrane Database Syst Rev Date: 2021-03-23
Authors: Olivia Cords; Leonardo Martinez; Joshua L Warren; Jamieson Michael O'Marr; Katharine S Walter; Ted Cohen; Jimmy Zheng; Albert I Ko; Julio Croda; Jason R Andrews Journal: Lancet Public Health Date: 2021-03-22
Authors: Katharine S Walter; Leonardo Martinez; Denise Arakaki-Sanchez; Victor G Sequera; G Estigarribia Sanabria; Ted Cohen; Albert I Ko; Alberto L García-Basteiro; Zulma Vanessa Rueda; Rafael A López-Olarte; Marcos A Espinal; Julio Croda; Jason R Andrews Journal: Lancet Date: 2021-04-08 Impact factor: 202.731
Authors: Flora Martinez Figueira Moreira; Renu Verma; Paulo Cesar Pereira Dos Santos; Alessandra Leite; Andrea da Silva Santos; Rafaele Carla Pivetta de Araujo; Bruna Oliveira da Silva; Júlio Henrique Ferreira de Sá Queiroz; David H Persing; Erik Södersten; Devasena Gnanashanmugam; Purvesh Khatri; Julio Croda; Jason R Andrews Journal: EClinicalMedicine Date: 2021-03-06
Authors: Katharine S Walter; Mariana Bento Tatara; Kesia Esther da Silva; Flora Martinez Figueira Moreira; Paulo Cesar Pereira Dos Santos; Dândrea Driely de Melo Ferrari; Eunice Atsuko Cunha; Jason R Andrews; Julio Croda Journal: Emerg Infect Dis Date: 2021-03 Impact factor: 6.883